Literature DB >> 6759265

Glucose modulation of insulin and glucagon secretion in nondiabetic and diabetic man.

P M Hollander, C M Asplin, J P Palmer.   

Abstract

To ascertain whether the ability of glucose to influence the pancreatic islets response to a nonglucose stimulus is normal in type II diabetics, we have evaluated the modulating effect (Md) of the plasma glucose level (PG) on the acute insulin response (IRI) and glucagon response (IRG) to intravenous arginine in noninsulin-dependent diabetics (NIDDM) and nondiabetics (ND). MdIRI or MdIRG is the change in the hormonal response to arginine resulting from changes in plasma glucose level divided by the change in plasma glucose. Md has been determined over two ranges of PG: between normal fasting PG (level I) and mild hyperglycemia (approximately 160 mg/dl, level II) and between mild hyperglycemia and marked hyperglycemia (approximately 350 mg/dl, level III). Increases in PG augmented the IRI response in both groups, but the degree of augmentation was impaired in the NIDDM group. MDIRI for ND and NIDDM between levels I and II were 20 +/- 3 and 1.9 +/- 0.6, respectively, and between levels II and III were 23 +/- 5 and 2.3 +/- 0.5, respectively (P less than 0.01). MdIRI correlated with fasting PG in ND and NIDDM. Changes in PG resulted in equivalent changes in the IRG response to arginine in both groups. MdIRG for level I to II was -6.2 +/- 1.0 and -6.0 +/- 1.2, and for level II and III was -0.9 +/- 0.4 and -1.2 +/- 0.5 in ND and NIDDM, respectively. The impairment of MDIRI and its relationship to fasting PG in NIDDM support the hypothesis that fasting hyperglycemia may be, in part, a compensatory mechanism for maintaining beta-cell response to nonglucose stimuli, thereby maintaining basal insulin levels. MdIRG was normal in NIDDM when evaluated at comparable glucose levels in the ND and NIDDM groups.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6759265     DOI: 10.2337/diab.31.6.489

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  7 in total

Review 1.  Alpha cell function in health and disease: influence of glucagon-like peptide-1.

Authors:  B E Dunning; J E Foley; B Ahrén
Journal:  Diabetologia       Date:  2005-08-13       Impact factor: 10.122

2.  How does glucose regulate the human pancreatic A cell in vivo?

Authors:  C M Asplin; P M Hollander; J P Palmer
Journal:  Diabetologia       Date:  1984-03       Impact factor: 10.122

Review 3.  Review of methods for measuring β-cell function: Design considerations from the Restoring Insulin Secretion (RISE) Consortium.

Authors:  Tamara S Hannon; Steven E Kahn; Kristina M Utzschneider; Thomas A Buchanan; Kristen J Nadeau; Philip S Zeitler; David A Ehrmann; Silva A Arslanian; Sonia Caprio; Sharon L Edelstein; Peter J Savage; Kieren J Mather
Journal:  Diabetes Obes Metab       Date:  2017-06-22       Impact factor: 6.577

4.  Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.

Authors:  W K Ward; D C Bolgiano; B McKnight; J B Halter; D Porte
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

5.  Paradoxical inhibition of insulin secretion by glucose in non-insulin-dependent diabetic patients.

Authors:  M Linstow; K J Mikines; F Dela; H Galbo
Journal:  Acta Diabetol       Date:  1995-03       Impact factor: 4.280

6.  The permissive effect of glucose, tolbutamide and high K+ on arginine stimulation of insulin release in isolated mouse islets.

Authors:  M P Hermans; W Schmeer; J C Henquin
Journal:  Diabetologia       Date:  1987-08       Impact factor: 10.122

7.  Adaptation of ovine fetal pancreatic insulin secretion to chronic hypoglycaemia and euglycaemic correction.

Authors:  Sean W Limesand; William W Hay
Journal:  J Physiol       Date:  2002-10-04       Impact factor: 5.182

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.